Ninlaro (Ixazomib)

Ninlaro (Ixazomib)

Ninlaro

Ixazomib

Capsules: 4 mg, 3 mg, and 2.3 mg

Takeda Pharmaceuticals America, Inc.

Medical Use

NINLARO, a proteasome inhibitor, is prescribed alongside lenalidomide and dexamethasone for treating multiple myeloma in patients who have undergone at least one prior therapy. Known as ixazomib, this oral medication is used to combat multiple myeloma, a cancer affecting white blood cells, in combination with other drugs. Approved in the US since November 2015 and in the EU since November 2016, ixazomib is specifically indicated for adults with multiple myeloma after at least one previous treatment. It has not been tested in children or adolescents under 18.